Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy

Chemotherapy-associated cardiotoxicity can present as a spectrum from arrhythmia to acute congestive heart failure. Unlike anthracyclines, proteasome inhibitors - for example, bortezomib - are not notorious for causing cardiotoxicity in absence of pre-existing cardiac dysfunction or without concomit...

Full description

Saved in:
Bibliographic Details
Published in:Journal of community hospital internal medicine perspectives 2015-01, Vol.5 (6), p.28982-3
Main Authors: Meseeha, Marcelle G, Kolade, Victor O, Attia, Maximos N
Format: Article
Language:English
Subjects:
Atherosclerosis
bortezomib
Cancer
Cancer therapies
Cardiology
Cardiomyopathy
cardiotoxicity
Cardiovascular disease
Case Report
Chemotherapy
Coronary vessels
Drug dosages
Family medical history
Funding
Heart attacks
Heart failure
Hospice care
Multiple myeloma
Patients
proteasome inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chemotherapy-associated cardiotoxicity can present as a spectrum from arrhythmia to acute congestive heart failure. Unlike anthracyclines, proteasome inhibitors - for example, bortezomib - are not notorious for causing cardiotoxicity in absence of pre-existing cardiac dysfunction or without concomitant use of other cardiotoxic agents. We describe a 66-year-old woman with end-stage renal disease who developed acute dyspnea hours after a third treatment with bortezomib for IgG kappa myeloma. The Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) between bortezomib and acute left ventricular dysfunction. Patients receiving proteasome inhibitors should be closely monitored for evidence of cardiac dysfunction during treatment.
ISSN:2000-9666
2000-9666
DOI:10.3402/jchimp.v5.28982